These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 8364945)

  • 1. Antihypertensive efficacy of FK906, a novel human renin inhibitor.
    Ogihara T; Nagano M; Higaki J; Higashimori K; Masuo K; Mikami H
    Clin Ther; 1993; 15(3):539-48. PubMed ID: 8364945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients.
    Denolle T; Luo P; Guyene TT; Cazaubon C; Sissmann J; Corvol P; Ménard J
    Arzneimittelforschung; 1993 Feb; 43(2A):255-9. PubMed ID: 8498973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Ali MA; Jin J; Keefe DL
    J Hypertens; 2008 Mar; 26(3):589-99. PubMed ID: 18300872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
    Wallis EJ; Ramsay LE; Hettiarachchi J
    Clin Pharmacol Ther; 1998 Oct; 64(4):439-49. PubMed ID: 9797801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin inhibition in hypertension.
    Gradman AH; Kad R
    J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
    Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
    Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma renin and noradrenalin levels during hypotensive therapy using acebutolol (author's transl)].
    Plouin PF; Comoy E; Bohuon C; Corvol P; Ménard J
    Nouv Presse Med; 1979 May; 8(23):1905-9. PubMed ID: 461152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antihypertensive treatment based on plasma renin activity: An open label observational study.
    Leotta G; Rabbia F; Testa E; Totaro S; Abram S; Milan A; Mulatero P; Veglio F
    Blood Press; 2010 Aug; 19(4):218-24. PubMed ID: 20367559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study.
    Akram J; Sheikh UE; Mahmood M; Donnelly R
    Curr Med Res Opin; 2007 Dec; 23(12):2929-36. PubMed ID: 17931463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.
    Brown MJ; Coltart J; Gunewardena K; Ritter JM; Auton TR; Glover JF
    Clin Sci (Lond); 2004 Aug; 107(2):167-73. PubMed ID: 15040783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.